Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed FCF Margin for 4 consecutive years, with 344243100.0% as the latest value for Q4 2023.

  • On a quarterly basis, FCF Margin fell 34423750523.0% to 344243100.0% in Q4 2023 year-over-year; TTM through Sep 2024 was 1724492300.0%, a 172448668417.0% decrease, with the full-year FY2023 number at 6947.87%, up 730549.0% from a year prior.
  • FCF Margin was 344243100.0% for Q4 2023 at Inhibikase Therapeutics, down from 5159.16% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 200.41% in Q3 2020 to a low of 344243100.0% in Q4 2023.
  • A 4-year average of 21539540.75% and a median of 4540.49% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 20509540bps in 2022, then plummeted 2000000000bps in 2023.
  • Inhibikase Therapeutics' FCF Margin stood at 555.42% in 2020, then tumbled by -37833bps to 210690.17% in 2021, then skyrocketed by 97bps to 5594.77% in 2022, then tumbled by -6152840bps to 344243100.0% in 2023.
  • Per Business Quant, the three most recent readings for IKT's FCF Margin are 344243100.0% (Q4 2023), 5159.16% (Q3 2023), and 3921.82% (Q2 2023).